Evidence map›Paper›PMID 41929162›Full record

ArticlebioRxiv : the preprint server for biology2026

Activation of the protective arm of renin-angiotensin system enhances mitochondrial turnover improving respiration and decreasing integrated stress response in a human Complex III deficiency model.

Lucía Fernández-Del-Río, Andrea Eastes, David Rincón Fernández Pacheco, Nikole Scillitani, Jasmine Garza, Matthew Dugan, Matheus Pinto de Oliveira, Pradnya Kadam, Iman Gauhar, Karel Erion and 6 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Lucía Fernández-Del-RíoDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, USA.ORCID 0000-0001-5657-2700
Andrea EastesDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, USA.ORCID 0000-0002-9271-1891
David Rincón Fernández PachecoBoard of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, USA.ORCID 0000-0001-6217-3757
Nikole ScillitaniDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, USA.
Jasmine GarzaMitochondria and Metabolism Core, University of California, Los Angeles, USA.
Matthew DuganMitochondria and Metabolism Core, University of California, Los Angeles, USA.
Matheus Pinto de OliveiraCapacity Bio Inc., Los Angeles, USA.ORCID 0000-0002-2124-8799
Pradnya KadamDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, USA.ORCID 0009-0009-5079-2927
Iman GauharDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, USA.
Karel ErionCapacity Bio Inc., Los Angeles, USA.ORCID 0000-0001-7555-5199
Kathleen RodgersCenter for Innovation in Brain Science, University of Arizona, Tucson, USA.
Kevin GaffneyCapacity Bio Inc., Los Angeles, USA.
Amy WangCapacity Bio Inc., Los Angeles, USA.
Marc LiesaDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, USA.ORCID 0000-0002-5909-8570
Cristiane BenincáDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, USA.ORCID 0000-0001-7933-860X
Orian Shaul ShirihaiDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, USA.ORCID 0000-0001-8466-3431

Funding

OPTIMIZATION OF NANOPARTICLE TUMOR-LOCALIZATION AND DRUG-LOADINGFOR TREATING MESOTHELIOMAR01CA232056 · NCI · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI COLSON, YOLONDA L, GRINSTAFF, MARK W. · 2019 to 2023
$2.7M
Lysosomal Regeneration (LysoGen) and Rescue as a Treatment for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)R01DK141923 · NIDDK · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI MARK W. GRINSTAFF, Orian S Shirihai · 2024 to 2026
$1.9M
Role of the heme-related mitochondrial antioxidant ABCB10 in alcoholic liver diseaseR01AA026914 · NIAAA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SHIRIHAI, ORIAN S · 2019 to 2022
$1.4M
NCI NIH HHS R01 CA232056NIAAA NIH HHS R01 AA026914NIDDK NIH HHS R01 DK141923
6 · The paper itself

Abstract

Primary mitochondrial diseases are clinically and genetically heterogeneous disorders, commonly caused by defects in the oxidative phosphorylation system. This heterogeneity presents major challenges for therapeutic development; however, a shared hallmark across these diseases is the accumulation of dysfunctional mitochondria. Enhancing mitochondrial turnover, by activating the selective degradation of dysfunctional mitochondria via mitophagy, concurrently with the activation of mitochondrial biogenesis, could represent a shared therapeutic strategy for mitochondrial diseases. Here, we describe a novel mitophagy inducer, CAP-1902. CAP-1902 is a new agonist of the MAS G-Protein Coupled Receptor (MasR). In fibroblasts from patients carrying a

Indexed as

AMPKFUNDC-1MAS receptormitochondrial biogenesismitophagyPGC1α

Identifiers

PMID41929162
PMCPMC13041836

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.